Legal considerations of clinical guidelines
Dr Ash Samanta and his colleagues (March 2003 JRSM 1 ) have produced a clear and valuable account of the place of clinical guidelines in the conduct of clinical negligence cases. Inevitably their message is principally directed at lawyers, including judges who have the conduct of cases. Two matters arising from their article give me concernnamely, prevention of medical errors which lead to litigation, and the provision of the National Institute of Clinical Excellence (NICE) recommendations to clinicians.
There needs to be much greater emphasis on prevention rather than investigating possible changes that would reduce costs. I think clinical guidelines and NICE reports have a very important part to play in reducing the number of claims. I think also they will lead to more successful outcomes for deserving claimants. Nothing will change unless clinicians receive the NICE reports and guidelines. I suggest it is for the specialty associations to send this material regularly to all trainees and consultants. It would be sensible also to provide medical students with this information during their clinical training. It would I am sure have a long-term beneficial effect. In their otherwise excellent review Dr Samanta and his colleagues (March 2003 JRSM 1 ) assert that 'clinical guidelines are systematically developed, evidence-based, clinically workable statements that aim to provide consistent and high quality care for patients', and that because 'guidelines from NICE . . . may be seen as the crème de la crème of authoritative bodies' it follows that their pronouncements are increasingly likely to inform the standard of care in negligence'. This is a dangerously illogical assumption to make: for all the diversity of lay and medical expertise available to NICE, the content of their guidelines is becoming increasingly proscriptive, and, in some cases, advocates a radical departure from pragmatic medical practice. The recent furore over the use of ultrasound locating devices for placing central venous catheters is a case in point. [2] [3] [4] There are any number of criticisms that could be made of this document and its practical implementation, 5 but with regard to the quasi- 
Autonomy of the pregnant woman
Dr Beveridge and colleagues (February 2003 JRSM 1 ) describe a patient whose behaviour put her unborn child at risk but who could not be detained under the Mental Health Act. It was cases of this sort that in the 1990s led to a spate of court-authorized caesarean sections which drew criticism from the lay, legal and medical press. 2 Guidelines laid down following the cases of Re MB 3 and Re S 4 have been adopted by the Department of Health and it is now quite clear that the pregnant woman if competent can decide what treatment to accept or refuse. Her reasons may be rational or irrational, and she may offer no reasons whatever-more so since the fetus is not a legal entity in English law.
Beveridge et al. rightly obeyed the law as it stands, but there is no gainsaying that the unborn children of such vulnerable adults are at excess risk of an adverse outcome, including death, when they choose to distance themselves from healthcare. In South Tyneside we take the care of these individuals to their homes as much as possible and build up a relationship through a named midwife liaising with an obstetrician. The hope is that, by term, sufficient trust and rapport will have been established to achieve a supervised delivery. This is not always successful but is worth a try. There is evidence that combination therapy with rifabutin or rifampicin alongside clarithromycin has a synergistic effect, particularly against Mycobacterium avium-intracellulare complex. 2 This not only ensures maximum antimycobacterial activity but also may protect against the development of secondary clarithromycin resistance. Multidrug regimens employing standard antimycobacterials (isoniazid, ethambutol and/or streptomycin) used with the above combination have proven effective in cases of disseminated atypical mycobacterial infections, particularly in patients with AIDS. 3 With excision biopsy early diagnosis is feasible with tools such as the polymerase-chain-reaction linked ELISA with mycobacterial DNA probes. The antimicrobial susceptibility of atypical mycobacteria can be assessed rapidly in tissue specimens by use of mycobacteria growth indicator tubes, which also give an indication of minimum inhibitory concentrations. 4 These tools for rapid diagnosis, not yet widely available, can be helpful in decisions about postoperative chemotherapy. 
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